Resistance to Targeted Therapies in Breast Cancer
Springer International Publishing AG, 2018
133,25 €On orderDelivery: 2-3 weeks
We present an in-depth description of resistance to targeted therapies in breast cancer. Targeted therapies discussed here include those used to treat ER+ or Her2+ breast cancers (i.e., Tamoxifen or trastuzumab) or those targeting signaling pathways aberrantly activated in triple negative breast cancer (i.e., EGFR and Wnt signaling).
- ISBN-13
- 9783319888910
- ISBN-10
- 3319888919
- Publisher
- Springer International Publishing AG
- Year
- 2018
- Publication date
- 2018-06-23
- Pages
- 184
- Dimensions
- 235x155x